Home 
Find my MSL
Vaccine Stability Calculator
REPORT SUSPECTED ADVERSE REACTIONS 
Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
DISEASE STATES
Tebipenem
ADAPT PO: Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Tebipenem Compared to IV Ertapenem in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
PIVOT PO: A Study of Oral Tebipenem Pivoxil Hydrobromide Compared to Intravenous Imipenem-Cilastatin in Participants With Complicated Urinary Tract Infection or Acute Pyelonephritis
Ibrexafungerp
VANQUISH: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Antiviral Monoclonal Antibody (Vir-7832)
AGILE (Early Phase Platform Trial for COVID-19)
Antiviral Monoclonal Antibody (Vir-7832)
AGILE (Early Phase Platform Trial for COVID-19)
Gepotidacin
A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea
Ibrexafungerp
FURI: Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
GSK3882347 (FimH Antagonist)
Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections
Gepotidacin
A Study to Evaluate Efficacy and Safety of GEPOTIDACIN in the Treatment of Uncomplicated Urinary Tract Infection
Comparative Study to Evaluate Efficacy and Safety of GEPOTIDACIN to NITROFURANTOIN in Treatment of Uncomplicated Urinary Tract Infection
SIS: A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
Ibrexafungerp
CARES: Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris
0 results - Use filter to search Pipeline
Disclaimer
This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.
Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.
